{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:25:04Z","timestamp":1778081104749,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["PY2022034"],"award-info":[{"award-number":["PY2022034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clgc.2025.102334","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:17:50Z","timestamp":1742397470000},"page":"102334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Causal Associations Between the Presence of Prostate Cancer or Testosterone Levels and Bladder Cancer Risk: A Mendelian Randomization Study"],"prefix":"10.1016","volume":"23","author":[{"given":"Wenbiao","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yewen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2025.102334_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clgc.2025.102334_bib0002","first-page":"145","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102334_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer [J]","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.clgc.2025.102334_bib0004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer [J]","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102334_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity [J]","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102334_bib0006","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJM200007133430201","article-title":"Environmental and heritable factors in the causation of cancer\u2013analyses of cohorts of twins from Sweden, Denmark, and Finland","volume":"343","author":"Lichtenstein","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102334_bib0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.eururo.2023.04.020","article-title":"Genome-wide association study of bladder cancer reveals new biological and translational insights","volume":"84","author":"Koutros","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102334_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104539","article-title":"Arsenic exposure: a public health problem leading to several cancers","volume":"110","author":"Palma-Lara","year":"2020","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102334_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28208","article-title":"The association between human papillomavirus and bladder cancer: evidence from meta-analysis and two-sample mendelian randomization","volume":"95","author":"Sun","year":"2023","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102334_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.juro.2007.08.157","article-title":"Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy","volume":"179","author":"Bostrom","year":"2008","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102334_bib0011","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2018.09.034","article-title":"External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population-based analysis","volume":"75","author":"Moschini","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102334_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.ju.0000163459.57305.a1","article-title":"Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer","volume":"174","author":"Chrouser","year":"2005","journal-title":"J Urol"},{"issue":"16","key":"10.1016\/j.clgc.2025.102334_bib0013","doi-asserted-by":"crossref","first-page":"14710","DOI":"10.18632\/oncotarget.3817","article-title":"Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy","volume":"6","author":"Shiota","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.clgc.2025.102334_bib0014","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00345-018-2504-3","article-title":"The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer","volume":"37","author":"Moschini","year":"2019","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102334_bib0015","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.euf.2020.10.002","article-title":"Switching cancers: a systematic review assessing the role of androgen suppressive therapy in bladder cancer","volume":"7","author":"Kourbanhoussen","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.clgc.2025.102334_bib0016","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3945\/ajcn.115.118216","article-title":"Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies","volume":"103","author":"Haycock","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.clgc.2025.102334_bib0017","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"issue":"7944","key":"10.1016\/j.clgc.2025.102334_bib0018","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.clgc.2025.102334_bib0019","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","article-title":"Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","volume":"50","author":"Schumacher","year":"2018","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.clgc.2025.102334_bib0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41591-020-0751-5","article-title":"Using human genetics to understand the disease impacts of testosterone in men and women","volume":"26","author":"Ruth","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.clgc.2025.102334_bib0021","doi-asserted-by":"crossref","first-page":"e4471","DOI":"10.1210\/clinem\/dgab507","article-title":"Genome-wide association study of estradiol levels and the causal effect of estradiol on bone mineral density","volume":"106","author":"Schmitz","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.clgc.2025.102334_bib0022","first-page":"1961","article-title":"Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic","volume":"45","author":"Bowden","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102334_bib0023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2307\/2171753","article-title":"Instrumental variables regression with weak instruments","volume":"65","author":"Staiger","year":"1997","journal-title":"Econometrica"},{"issue":"3","key":"10.1016\/j.clgc.2025.102334_bib0024","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1534\/genetics.110.122549","article-title":"One hundred years of pleiotropy: a retrospective","volume":"186","author":"Stearns","year":"2010","journal-title":"Genetics"},{"issue":"7","key":"10.1016\/j.clgc.2025.102334_bib0025","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102334_bib0026","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102334_bib0027","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ng.3809","article-title":"Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites","volume":"49","author":"Long","year":"2017","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.clgc.2025.102334_bib0028","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00345-023-04380-5","article-title":"External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy","volume":"41","author":"Minami","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2025.102334_bib0029","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/CMAR.S185867","article-title":"High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis","volume":"11","author":"Zhao","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clgc.2025.102334_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/10732748231177544","article-title":"Increased burden of second bladder cancer and rectal cancer in prostate cancer treated with radiotherapy: results from surveillance, epidemiology, and end results","volume":"30","author":"Lin","year":"2023","journal-title":"Cancer Control"},{"issue":"11","key":"10.1016\/j.clgc.2025.102334_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2022.06.021","article-title":"Clinical and histopathological features of bladder cancer following radiotherapy for prostate cancer: a comparative study","volume":"40","author":"Scher\u00f1uk","year":"2022","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102334_bib0032","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijrobp.2007.12.043","article-title":"Second primary cancer after radiotherapy for prostate cancer\u2013a seer analysis of brachytherapy versus external beam radiotherapy","volume":"72","author":"Abdel-Wahab","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102334_bib0033","doi-asserted-by":"crossref","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.clgc.2025.102334_bib0034","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/cncr.28769","article-title":"Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study","volume":"120","author":"Davis","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102334_bib0035","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2007.02.029","article-title":"Kaser-Hotz B. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer","volume":"68","author":"Schneider","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.clgc.2025.102334_bib0036","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41419-023-05882-1","article-title":"Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK\/JUP signalling","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.clgc.2025.102334_bib0037","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41388-019-0964-6","article-title":"Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated G\u03b1i protein\/MAPK\/MMP9 intracellular signaling","volume":"39","author":"Chen","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.clgc.2025.102334_bib0038","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12967-023-03972-4","article-title":"Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer","volume":"21","author":"Seok","year":"2023","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102334_bib0039","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.euf.2019.04.021","article-title":"Androgen suppression therapy is associated with lower recurrence of non-muscle-invasive bladder cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.clgc.2025.102334_bib0040","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.juro.2016.08.006","article-title":"Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5\u03b1-reductase inhibitor","volume":"197","author":"Shiota","year":"2017","journal-title":"J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:30:50Z","timestamp":1762551050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1558767325000357"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102334","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Causal Associations Between the Presence of Prostate Cancer or Testosterone Levels and Bladder Cancer Risk: A Mendelian Randomization Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102334"}}